For this reason, in recent years, medical research, especially tumor physiology research, has focused on the study of the Axl/Gas6 molecular axis, resulting in the development of different classes of therapeutic agents, from kinase inhibitors to anti-receptor antibodies and aptamers, even if no drug has been FDA-approved to date [16,17]. Here, AXL is linked to neoplasm.